These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35999128)

  • 21. Defining the gap in heart failure treatment in patients with cardiac implantable electronic devices.
    Salimian S; Moghaddam N; Deyell MW; Virani SA; Bennett MT; Krahn AD; Andrade JG; Hawkins NM
    Clin Res Cardiol; 2023 Jan; 112(1):158-166. PubMed ID: 36329250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry.
    Chang HY; Wang CC; Wei J; Chang CY; Chuang YC; Huang CL; Chong E; Lin JL; Mar GY; Chan KC; Kuo JY; Wang JH; Chen ZC; Tseng WK; Cherng WJ; Yin WH
    J Chin Med Assoc; 2017 Dec; 80(12):750-757. PubMed ID: 29033112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.
    Ezekowitz JA; McMullan CJ; Westerhout CM; Piña IL; Lopez-Sendon J; Anstrom KJ; Hernandez AF; Lam CSP; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Voors AA; Koglin J; Armstrong PW; Butler J;
    Circ Heart Fail; 2023 Sep; 16(9):e010599. PubMed ID: 37417824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.
    Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE
    Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction.
    McCullough PA; Mehta HS; Barker CM; Van Houten J; Mollenkopf S; Gunnarsson C; Ryan M; Cork DP
    Clin Cardiol; 2021 Sep; 44(9):1192-1198. PubMed ID: 34342033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
    Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
    ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.
    Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE
    Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.
    Heywood JT; Fonarow GC; Yancy CW; Albert NM; Curtis AB; Gheorghiade M; Inge PJ; McBride ML; Mehra MR; O'Connor CM; Reynolds D; Walsh MN
    Circ Heart Fail; 2010 Sep; 3(5):596-605. PubMed ID: 20634483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
    Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
    J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice.
    Savarese G; Lindberg F; Christodorescu RM; Ferrini M; Kumler T; Toutoutzas K; Dattilo G; Bayes-Genis A; Moura B; Amir O; Petrie MC; Seferovic P; Chioncel O; Metra M; Coats AJS; Rosano GMC
    Eur J Heart Fail; 2024 Jun; 26(6):1408-1418. PubMed ID: 38515385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction.
    Lee YC; Lin JK; Ko D; Cheng S; Patorno E; Glynn RJ; Tsacogianis T; Kim DH
    J Am Geriatr Soc; 2023 Oct; 71(10):3110-3121. PubMed ID: 37345734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Fonarow GC; DeVore AD; Sharma PP; Vaduganathan M; Albert NM; Duffy CI; Hill CL; McCague K; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Butler J
    J Am Coll Cardiol; 2019 May; 73(19):2365-2383. PubMed ID: 30844480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial.
    Cox ZL; Zalawadiya SK; Simonato M; Redfors B; Zhou Z; Kotinkaduwa L; Zile MR; Udelson JE; Lim DS; Grayburn PA; Mack MJ; Abraham WT; Stone GW; Lindenfeld J
    JACC Heart Fail; 2023 Jul; 11(7):791-805. PubMed ID: 37115135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Optimization of Medical Treatment on Long-Term Survival of Patients With Heart Failure After Implantable Cardioverter Defibrillator and Cardiac Resynchronization Device Implantation (from the French National EGB Database).
    Massoullié G; Chouki C; Mulliez A; Rossignol P; Ploux S; Pereira B; Reuillard A; Jean F; Andronache M; Eschalier A; Motreff P; Clerfond G; Bordachar P; Authier N; Eschalier R
    Am J Cardiol; 2018 Mar; 121(6):725-730. PubMed ID: 29402420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
    DeFilippis EM; Butler J; Vaduganathan M
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29138249
    [No Abstract]   [Full Text] [Related]  

  • 37. Harnessing the Potential of Primary Care Pharmacists to Improve Heart Failure Management.
    Slade J; Lee M; Park J; Liu A; Heidenreich P; Allaudeen N
    Jt Comm J Qual Patient Saf; 2022 Jan; 48(1):25-32. PubMed ID: 34848159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Pharmacist-Led Heart Failure Clinic on Optimization of Guideline-Directed Medical Therapy (PHARM-HF).
    Patil T; Ali S; Kaur A; Akridge M; Eppes D; Paarlberg J; Parashar A; Jarmukli N
    J Cardiovasc Transl Res; 2022 Dec; 15(6):1424-1435. PubMed ID: 35501544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation.
    Roth GA; Poole JE; Zaha R; Zhou W; Skinner J; Morden NE
    J Am Coll Cardiol; 2016 Mar; 67(9):1062-1069. PubMed ID: 26940927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A risk score to predict the absence of left ventricular reverse remodeling: Implications for the timing of ICD implantation in primary prevention.
    Pérez-Rodon J; Galve E; Pérez-Bocanegra C; Soriano-Sánchez T; Recio-Iglesias J; Domingo-Baldrich E; Alzola-Guevara M; Ferreira-González I; Marsal JR; Ribera-Solé A; Gutierrez García-Moreno L; Cruz-Carlos LM; Rivas-Gandara N; Roca-Luque I; Francisco-Pascual J; Evangelista-Masip A; Moya-Mitjans À; García-Dorado D
    J Cardiol; 2018 May; 71(5):505-512. PubMed ID: 29183646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.